Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Feb 28, 2024 10:44am
208 Views
Post# 35903770

1 day to go

1 day to goWell yesterdays bump was short lived. February 28th today and again no news. Only 1 day left in February  to announce 1st dosing and if I was a betting man it doesn't happen.

Something not adding up here. Where is the revised February first dosing? Why have we not been updated?

Management has yet to even announce sites for Turkey or Canada, or if they have I did not see that information?

Are we even actively recruiting? I suspect we first need to get sites and doctors on board.

I have a strong gut feeling we will not announce 1st dosing which will be pushed out further again. That would be terrible and damaging for corporate credibility. This should really make Raymond James analyst bullish.

Management has until tomorrow to hit their announced date or will they fumble the ball again.

Yesterday news was a pleasant surprise but it was also "Pre IND" meeting and we are looking at summer potential commencement but one can only take managements comments about commencement dates with a grain of salt.

Management mentioned that this IND phase trial for cilastatin in toxin related AKI will commence along side the New phase 2 AKI trial announced for Turkey and Canada. Now reading the tea leaves are they covertly stating the current AKI trial is being delayed until the summer. I am not sure but its not looking good for February first dosing.

If past news releases are any indication this IND commencement will be many months later and potentially not starting until 2025 based on past performance with achieving announced dates.

I am bullish and long this stock but management keeps dropping the ball in my opinion.

I am starting to feel yesterday's news release was fluff and was to distract shareholders regarding another delay coming with Turkey first dosing. Communication with this management team is terrible. If we had institutions invested they would likely have a board position and would keep management accountable.

Frudtration is really settling in here for me.
<< Previous
Bullboard Posts
Next >>